NAIROBI, Kenya — The Pharmacy and Poisons Board (PPB) has issued a public alert warning healthcare providers, distributors, and patients against the use of a falsified batch of the cancer treatment drug Phesgo currently circulating in the Kenyan market.
In a statement dated May 25, 2026, the Board identified the falsified product as Phesgo (Pertuzumab/Trastuzumab) 600mg/600mg in 10ml, Batch Number C5290S20.
PPB warned that the counterfeit product poses a serious threat to patient safety because its quality, safety, and effectiveness cannot be guaranteed.
PPB Identifies Major Product Discrepancies
According to the Board, investigations conducted through post-marketing surveillance established that Batch Number C5290S20 does not match any authentic batch produced by pharmaceutical manufacturer Roche.
The regulator further noted that the falsified product contains a white powder, contrary to genuine Phesgo, which is supplied as a ready-to-use liquid solution intended for subcutaneous administration.
“The falsified batch may contain incorrect, insufficient, or harmful ingredients, and its quality, safety, and efficacy cannot be guaranteed,” PPB stated.
“Use of this product poses a serious risk to patient safety and public health,” the Board added.
Healthcare Providers Told to Stop Distribution Immediately
The Board directed procurement agencies, wholesalers, distributors, retailers, pharmacists, and all healthcare professionals to immediately stop distributing or using the affected batch.
PPB also urged all players in the pharmaceutical supply chain to source health products exclusively from licensed manufacturers, importers, and distributors.
“Procuring from unlicensed sources endangers patients and constitutes a violation of the Pharmacy and Poisons Act,” the statement warned.
The regulator said it would work alongside investigative agencies to pursue individuals or entities involved in the distribution of falsified medicines.
Reporting Channels Released
Members of the public and healthcare professionals have been urged to report any suspected counterfeit or substandard medicines through official PPB reporting channels.
Reports can be submitted through the Board’s online portal, USSD code *271#, the mPvERS mobile application, email or telephone contacts provided by the regulator.
The statement was signed by PPB Acting Chief Executive Officer Dr Ahmed I. Mohamed.
Concerns Over Counterfeit Medicines
The alert highlights growing concerns over the circulation of counterfeit and falsified medicines within Kenya and globally, particularly high-value specialised treatments such as cancer drugs.
Public health experts have repeatedly warned that falsified medicines can lead to treatment failure, drug resistance, severe adverse reactions, and loss of life, especially among vulnerable patients undergoing specialised treatment.
